Lamotrigine as an add-on treatment for depersonalization disorder: A retrospective study of 32 cases

被引:21
|
作者
Sierra, Mauricio [1 ]
Baker, Dawn [1 ]
Medford, Nicholas [1 ]
Lawrence, Emma [1 ]
Patel, Maxine [1 ]
Phillips, Mary L. [1 ]
David, Anthony S. [1 ]
机构
[1] Inst Psychiat, Depersonalisat Res Unit, London SE5 8AZ, England
关键词
depersonalization; derealization; dissociation; lamotrigine; depression; selective serotonin reuptake inhibitor; glutamate; CDS;
D O I
10.1097/01.WNF.0000228368.17970.DA
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: Depersonalization disorder (DPD) is a chronic condition characterized by the persistent subjective experience of unreality and detachment from the self. To date, there is no known treatment. Lamotrigine as sole agent was not found to be effective in a previous small double-blind, randomized crossover trial. However, evidence from open trials suggests that it may be beneficial as an add-on medication with antidepressants. Methods: We report here an extended series of 32 patients with DPD in whom lamotrigine was prescribed as an augmenting medication. Most of the patients were receiving selective serotonin reuptake inhibitors. Results: Fifty-six percent (n = 18) of patients had a more than or equal to 30% reduction on the Cambridge Depersonalization Scale score at follow-up. Both maximum dose of lamotrigine used and before treatment Cambridge Depersonalization Scale scores showed positive correlations with the percentage of response. Conclusions: The results of this trial suggest that a significant number of patients with DPD may respond to lamotrigine when combined with antidepressant medication. The results are sufficiently positive to prompt a larger controlled evaluation of lamotrigine as "add-on' treatment in DPD.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 50 条
  • [41] Mindful Yoga Intervention as Add-on to Treatment as Usual for Young Women With Major Depressive Disorder: Results From a Randomized Controlled Trial
    Vollbehr, Nina K. K.
    Hoenders, H. J. Rogier
    Bartels-Velthuis, Agna A. A.
    Nauta, Maaike H. H.
    Castelein, Stynke
    Schroevers, Maya J. J.
    Stant, A. Dennis
    Albers, Casper J. J.
    de Jong, Peter J. J.
    Ostafin, Brian D. D.
    JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 2022, 90 (12) : 925 - 941
  • [42] Polaprezinc (Zinc-l-Carnosine Complex) as an Add-on Therapy for Binge Eating Disorder and Bulimia Nervosa, and the Possible Involvement of Zinc Deficiency in These Conditions A Pilot Study
    Sakae, Kensaku
    Suka, Machi
    Yanagisawa, Hiroyuki
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (06) : 599 - 606
  • [43] Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder
    Galuszko-Wegielnik, Maria
    Jakuszkowiak-Wojten, Katarzyna
    Wiglusz, Mariusz Stanislaw
    Cubala, Wieslaw Jerzy
    Pastuszak, Michal
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [44] Role of Lamotrigine Augmentation in Treatment-Resistant Obsessive Compulsive Disorder: A Retrospective Case Review from South Asia
    Hussain, Arshad
    Dar, Mansoor Ahmad
    Wani, Rayees Ahmad
    Shah, Majid Shafi
    Jan, Mohd Muzzaffar
    Malik, Yasir A.
    Chandel, Rajesh Kumar
    Margoob, Mushtaq Ahmad
    INDIAN JOURNAL OF PSYCHOLOGICAL MEDICINE, 2015, 37 (02) : 154 - 158
  • [45] Add-on rTMS for treatment of depression:: a pilot study using stereotaxic coil-navigation according to PET data
    Herwig, U
    Lampe, Y
    Juengling, FD
    Wunderlich, A
    Walter, H
    Spitzer, M
    Schönfeldt-Lecuona, C
    JOURNAL OF PSYCHIATRIC RESEARCH, 2003, 37 (04) : 267 - 275
  • [46] Curcumin as an Add-On to Antidepressive Treatment: A Randomized, Double-Blind, Placebo-Controlled, Pilot Clinical Study
    Bergman, Joseph
    Miodownik, Chanoch
    Bersudsky, Yuly
    Sokolik, Shmuel
    Lerner, Paul P.
    Kreinin, Anatoly
    Polakiewicz, Jacob
    Lerner, Vladimir
    CLINICAL NEUROPHARMACOLOGY, 2013, 36 (03) : 73 - 77
  • [47] Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study
    Fountoulakis, Konstantinos N.
    Karavelas, Vangelis
    Moysidou, Stefania
    Mavridis, Dimitris
    Pastiadis, Konstantinos
    Petalidou, Nicole
    Nimatoudis, Ioannis
    Kasper, Siegfried
    PHARMACOPSYCHIATRY, 2019, 52 (04) : 193 - 202
  • [48] Effect of cranial electrotherapy stimulation as an add-on therapy on late-life generalized anxiety disorder: An open-label study
    Chu, Che-Sheng
    Chang, Cheng-Ho
    Pan, Chih-Chuan
    Chiang, Yung-Chih
    Kuo, Hsin-Ya
    Hsu, Tien-Wei
    Chen, Shiou-Lan
    Chen, Cheng-Sheng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2024, 123 (07) : 781 - 787
  • [49] The ACAMTO study-impact of add-on osteopathic treatment on adolescent patients with anorexia nervosa: study protocol for a randomized controlled trial
    Letranchant, Aurelie
    Montebello, Yunkyung Kim-de
    Bigre, Corinne Dugre-Le
    Wagner, Agathe
    Curt, Florence
    Silva, Jerome
    Nicolas, Isabelle
    Votadoro, Pablo
    Kalindjian, Nina
    Korchonnoff, Anna
    Gutierre, Andrea
    Novelli, Ana Beatriz
    Pham-Scottez, Alexandra
    Corcos, Maurice
    TRIALS, 2021, 22 (01)
  • [50] Treatment of major depression with a two-step tDCS protocol add-on to SSRI: Results from a naturalistic study
    Palm, Ulrich
    Goerigk, Stephan
    Kirsch, Beatrice
    Baeumler, Leonie
    Sarubin, Nina
    Hasan, Alkomiet
    Brunoni, Andre R.
    Padberg, Frank
    BRAIN STIMULATION, 2019, 12 (01) : 195 - 197